Frankfurt - Delayed Quote EUR

PHAXIAM Therapeutics S.A. (2E40.F)

Compare

1.7200

-0.0100

(-0.58%)

At close: January 31 at 9:48:30 PM GMT+1

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for 2E40.F

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PHAXIAM Therapeutics S.A. (2E40.F)

Comparisons

Indicators

Technicals

Corporate Events

2.26%

5.52%

9.69%

-6.93%

5.52%

-53.51%

-97.27%

-99.31%

Recent News: 2E40.F

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

PHAXIAM: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 31, 2024

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

PHAXIAM Reports Third-Quarter 2024 Financial Information

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024